Stay updated on Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial
Sign up to get notified when there's something new on the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page.
Latest updates to the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page
- Check6 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
- Check13 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.1%
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe European Myeloma Network has added new results related to Velcade, including updated definitions and metrics for progression-free survival (PFS), overall response rates (ORR), and MRD negativity rates, with a maximum follow-up time of 54.41 months, while previous entries regarding post-consolidation MRD negativity and various timelines for response assessments have been removed.SummaryDifference28%
- Check35 days agoNo Change Detected
- Check42 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.0%
- Check49 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study and includes a reference to the Contacts and Locations section.SummaryDifference1%
- Check64 days agoChange DetectedSeveral key medical and genetic resource links related to multiple myeloma and associated treatments have been removed, indicating a significant reduction in available information on this topic.SummaryDifference3%
Stay in the know with updates to Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Perseus Study: Daratumumab vs Standard in Untreated Myeloma Clinical Trial page.